Boston Scientific Corporation today announced positive 12-month primary endpoint results from the second phase of the ...

With careful consideration of several factors, many patients can avoid an overnight stay, reducing costs without sacrificing ...

Boston Scientific (BSX) announced positive 12-month primary endpoint results from the second phase of the ADVANTAGE AF clinical trial ...

Boston Scientific Corporation (NYSE: BSX) today announced positive 12-month primary endpoint results from the second phase of ...

The continued success of abelacimab throughout the AZALEA-TIMI 71 trials helps draw the drug closer to FDA approval, stated ...

For patients newly diagnosed with atrial fibrillation (AF) during hospitalization for other causes, most are not dispensed ...

Vektor Medical, a leader in non-invasive, AI-powered arrhythmia analysis technology, today announced the initiation of the ...

Thanks to healthcare reform, the hurdles to securing reimbursement and technology add-on payments have risen. Boston will need to invest more in clinical studies to demonstrate superiority of outcomes ...

Field Medical secures major funding to reimagine life-saving cardiac care through next-gen ablation therapies.

Field Medical Inc., a pioneer in cardiac pulsed field ablation (PFA) technology, today announced the successful closing of ...

The biomedical market’s latest technology for treating irregular heartbeats has made its way to the Flathead Valley, bringing ...